Prognostic factors in XXXX .

@entity1 @entity4557 @entity706 @entity5 @entity1893 @entity1349
The results obtained with the various types of treatment in @entity1893 are reviewed and the data from the recent EORTC trials are summarized. In @entity1 with Stage I follicular histology, regional radiotherapy (RT) alone gives excellent results. The long-term @entity4557 ( @entity4557 ) is high and relapsing @entity1 can be rescued by aggressive combination chemotherapy; initial chemotherapy with CVP improves @entity4557 but not @entity1349 ( @entity1349 ). In @entity1 with Stage I diffuse histology, the long-term survival is less satisfactory. CVP chemotherapy does not improve either @entity4557 or @entity1349 ; therefore if adjuvant chemotherapy is justified, it should be more aggressive than CVP. In @entity1 with Stage II follicular type, regional radiotherapy alone gives good results. The addition of abdominal bath irradiation to regional RT increases @entity4557 but not @entity1349 . After relapse, @entity1 can be rescued by combination chemotherapy. In @entity1 with Stage II diffuse histology, extended RT followed by CVP gives poor results and RT should be combined with more aggressive combination CT; the preliminary results of an integrated alternating regimen being excellent. In @entity1 with Stage III and IV follicular type, the 8 year @entity1349 of @entity1 treated with combination CT regimen (CHVP) followed by localized irradiation is approximately 55%, however the indications for the various types of treatment are still unclear. In @entity1 with diffuse Stage III and IV, the results obtained with a combination CT regimen (CHVP) are still unsatisfactory, but are better in @entity1 treated by a more aggressive CT regimen (CHVP-Bleo-VCR). Therefore aggressive CT associated with localized irradiation appears to be the best treatment. Further research should aim to identify the optimal combination CT regimen. In @entity1 with high grade @entity706 who have relapsed the use of bone marrow autografts will be investigated. The present data show that besides histological type and age, the main prognostic factor is total @entity5 body burden as assessed by clinical stage, number of involved lymph node areas, and bulk of the disease. The study of the biological characteristics of the disease may provide more powerful prognostic indicators.
